MARCHF1
Basic information
Region (hg38): 4:163524298-164384050
Previous symbols: [ "MARCH1" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MARCHF1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 13 | 13 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 13 | 0 | 0 |
Variants in MARCHF1
This is a list of pathogenic ClinVar variants found in the MARCHF1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
4-163528771-G-A | not specified | Uncertain significance (Feb 27, 2024) | ||
4-163528832-A-C | not specified | Uncertain significance (Oct 04, 2022) | ||
4-163528908-A-C | not specified | Uncertain significance (Jul 08, 2022) | ||
4-163529041-G-A | not specified | Uncertain significance (May 30, 2024) | ||
4-163585754-G-A | not specified | Uncertain significance (Jun 06, 2023) | ||
4-163585773-C-G | not specified | Uncertain significance (Oct 20, 2023) | ||
4-163585848-C-G | not specified | Uncertain significance (Oct 26, 2021) | ||
4-163585902-C-G | not specified | Uncertain significance (Oct 12, 2022) | ||
4-163613359-C-T | not specified | Uncertain significance (Nov 21, 2023) | ||
4-163613365-G-A | not specified | Uncertain significance (Dec 13, 2022) | ||
4-163854042-G-T | not specified | Uncertain significance (Dec 17, 2023) | ||
4-163854046-G-T | not specified | Uncertain significance (Dec 15, 2022) | ||
4-163854052-T-C | not specified | Uncertain significance (Jan 18, 2023) | ||
4-163854056-C-T | not specified | Uncertain significance (Oct 14, 2021) | ||
4-163854081-G-T | not specified | Uncertain significance (Apr 15, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
MARCHF1 | protein_coding | protein_coding | ENST00000503008 | 6 | 859753 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00868 | 0.980 | 125732 | 0 | 14 | 125746 | 0.0000557 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.41 | 115 | 166 | 0.692 | 0.00000943 | 1870 |
Missense in Polyphen | 37 | 78.764 | 0.46976 | 876 | ||
Synonymous | -0.198 | 62 | 60.0 | 1.03 | 0.00000332 | 569 |
Loss of Function | 2.21 | 6 | 15.4 | 0.390 | 8.81e-7 | 161 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000907 | 0.0000906 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.00 | 0.00 |
Finnish | 0.000139 | 0.000139 |
European (Non-Finnish) | 0.0000713 | 0.0000703 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: E3 ubiquitin-protein ligase that mediates ubiquitination of TFRC, CD86, FAS and MHC class II proteins, such as HLA-DR alpha and beta, and promotes their subsequent endocytosis and sorting to lysosomes via multivesicular bodies. By constitutively ubiquitinating MHC class II proteins in immature dendritic cells, down-regulates their cell surface localization thus sequestering them in the intracellular endosomal system. {ECO:0000269|PubMed:14722266, ECO:0000269|PubMed:18305173, ECO:0000269|PubMed:18389477, ECO:0000269|PubMed:19117940}.;
Recessive Scores
- pRec
- 0.0817
Intolerance Scores
- loftool
- 0.599
- rvis_EVS
- 0.04
- rvis_percentile_EVS
- 56.92
Haploinsufficiency Scores
- pHI
- 0.182
- hipred
- N
- hipred_score
- 0.498
- ghis
- 0.477
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.552
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- March1
- Phenotype
- immune system phenotype; hematopoietic system phenotype;
Gene ontology
- Biological process
- protein polyubiquitination;antigen processing and presentation of peptide antigen via MHC class II;immune response
- Cellular component
- lysosome;lysosomal membrane;endosome;endoplasmic reticulum membrane;plasma membrane;integral component of membrane;cytoplasmic vesicle membrane;early endosome membrane;late endosome membrane;trans-Golgi network membrane
- Molecular function
- ubiquitin-protein transferase activity;zinc ion binding;MHC protein binding;ubiquitin protein ligase activity